Adult ocular adnexal xanthogranulomatous disease associated with immunoglobulin G4-related disease: an unusual association
Abstract
Adult-onset xanthogranuloma (AOX) and immunoglobulin G4-related disease (IgG4-RD) are uncommon fibrosing conditions that may exhibit localized ocular manifestations and occasionally systemic symptoms. These conditions exhibit overlapping clinical and histological features, suggesting a potential correlation between them, although their exact relationship remains unclear. This paper presents the case of a black male patient exhibiting typical histological indications of both AOX and IgG4-RD. The patient responded positively to corticosteroid treatment.
References
- Kerstetter J, Wang J. Adult orbital xanthogranulomatous disease. Dermatol Clin 2015; 33: 457-63. DOI: https://doi.org/10.1016/j.det.2015.03.010
- Wallace ZS, Zhang Y, Perugino CA, Naden R, Choi HK, Stone JH. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 2019; 78: 406-12 DOI: https://doi.org/10.1136/annrheumdis-2018-214603
- Burris CKH, Rodriguez ME, Raven ML, Burkat CN, Albert DM. Adult-onset asthma and periocular xanthogranulomas associated with systemic IgG4-related disease. Am J Ophthalmol Case Rep 2016; 1: 34-7. DOI: https://doi.org/10.1016/j.ajoc.2016.03.006
- London J, Martin A, Soussan M, Badelon I, Gille T, Uzunhan Y, et al. Adult-onset asthma and periocular xanthogranuloma (AAPOX), a rare entity with a strong link to IgG4-related disease. Medicine 2015; 94: e1916. DOI: https://doi.org/10.1097/MD.0000000000001916
- Singh K, Rajan K, Eberhart C. Orbital necrobiotic xanthogranuloma associated with systemic IgG4 disease. Ocul Immunol Inflamm 2010; 18: 373-8. DOI: https://doi.org/10.3109/09273948.2010.490629
- Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 2020; 72: 7-19. DOI: https://doi.org/10.1002/art.41120
- Andron AA, Nair AG, Della Rocca D, Della Rocca RC, Reddy HS. Concomitant adult onset xanthogranuloma and IgG4-related orbital disease: a rare occurrence. Orbit 2022; 41: 108-11. DOI: https://doi.org/10.1080/01676830.2020.1814353
- Asproudis I, Kanari M, Ntountas I, Ragos V, Goussia A, Batistatou A, et al. Successful treatment with rituximab of IgG4-related disease coexisting with adult-onset asthma and periocular xanthogranuloma. Rheumatol Int 2020; 40: 671-7. DOI: https://doi.org/10.1007/s00296-019-04409-2
- Leung KCP, Ko P, Ho CHJ, Ko TCS. Adult onset xanthogranuloma associated with IgG4-related disease. Korean J Ophthalmol 2018; 32: 424-5. DOI: https://doi.org/10.3341/kjo.2017.0145
- McKelvie P, McNab AA, Hardy T, Rathi V. Comparative study of clinical, pathological, radiological, and genetic features of patients with adult ocular adnexal xanthogranulomatous disease, Erdheim-Chester disease, and IgG4-related disease of the orbit/ocular adnexa. Ophthalmic Plast Reconstr Surg 2017; 33: 112-9. DOI: https://doi.org/10.1097/IOP.0000000000000661
- Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366: 539-51. DOI: https://doi.org/10.1056/NEJMra1104650
- Pomponio G, Olivari D, Mattioli M, Angeletti A, Rossetti G, Goteri G, et al. Sustained clinical response after single course of rituximab as first-line monotherapy in adult-onset asthma and periocular xanthogranulomas syndrome associated with IgG4-related disease. Medicine 2018; 97: e11143. DOI: https://doi.org/10.1097/MD.0000000000011143
- Ortiz Salvador JM, Subiabre Ferrer D, Pérez Ferriols A. Adult Xanthogranulomatous Disease of the Orbit: Clinical Presentations, Evaluation, and Management. Actas Dermosifiliogr 2017; 108: 400-6. DOI: https://doi.org/10.1016/j.adengl.2017.03.030
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2024 the Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.